USANA Health Sciences (USNA) Q3 2026 earnings summary

Executive summary

• Q3 net sales were $205.9M, down 3.6% YoY reported and 5.6% excluding currency; Hiya growth was offset by lower Core Nutritional and Rise Wellness sales.

• Q3 net loss attributable was $5.6M versus $6.5M; nine-month net loss was $19.4M, including a $29.1M non-cash Hiya goodwill impairment.

• FY2026 adjusted EBITDA outlook was reduced to $77M; cash was $178.9M with no debt at quarter-end.

Financial highlights

• Q3 diluted loss per share was $0.30 versus $0.36; adjusted diluted loss per share was $0.11 versus $0.15.

• Adjusted EBITDA attributable was $12.052M, down 13% YoY and 44% sequentially.

• Nine-month operating cash flow was $45.0M versus $25.7M; free cash flow was $35.7M versus $14.7M.

• Consolidated gross margin was 76.3%, down 90 bps YoY; Q3 operating loss was $1.4M.

Outlook and guidance

• FY2026 net sales outlook approaches $900M; adjusted EBITDA is $77M, net loss $16M, diluted loss per share $0.90 and adjusted diluted EPS $0.55.

• Segment sales outlook: Core Nutritional $740M, Hiya $130M and Rise Wellness $30M; Core includes expected favorable FX impact of ~$20M.

• Hiya Q4 net sales and adjusted EBITDA are expected to improve sequentially; outlook reflects increased acquisition investment and weaker Rise expectations, partly offset by stronger Core profitability.

• Rise outlook assumes Q4 retail orders ship as scheduled; delays into Q1 2027 could put FY2026 results below outlook.